Experimental drug shows promise against deadly pancreatic cancer
Summary
A new pill called daraxonrasib helped people with advanced pancreatic cancer live almost twice as long compared to standard chemotherapy. The drug targets a common mutation in the cancer and showed fewer severe side effects, offering hope for better treatment.Key Facts
- Daraxonrasib blocks a mutated protein linked to over 90% of pancreatic cancers.
- In a study with 500 patients, those taking the drug lived 13.2 months on average versus 6.7 months with chemotherapy.
- The drug caused fewer serious side effects, mainly skin rash and mouth sores.
- Patients stayed on daraxonrasib longer and reported less pain and better quality of life.
- The study results were published in the New England Journal of Medicine and announced at a major cancer meeting.
- The FDA plans to speed up the review of daraxonrasib and is allowing expanded access for some patients.
- Pancreatic cancer is very deadly, with about 67,000 new U.S. cases and 52,000 deaths expected this year.
- Researchers hope the drug could be useful earlier in treatment and might help more patients become eligible for surgery.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.